PHILADELPHIA, Nov. 11, 2026 (GLOBE NEWSWIRE) — Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed digital asset treasury, infrastructure, and services company providing institutional access to the Solana ecosystem, today announced its results for the quarter ended September 30, 2026.

The third quarter was defined by streamlined operations and the expansion of its treasury holdings. The Company generated $3.4 million in revenue as its self-reinforcing flywheel began to turn, reducing operating costs to their lowest level yet. Headlining the quarter, the Company priced an approximately $15 million registered direct offering at a 5% premium to net asset value per share and used the proceeds to purchase approximately 125 thousand SOL.

Third Quarter Operational Highlights

  • Pacific Backbone moved from build-out to operation, with approximately 1.3 million SOL of total stake delegated as of September 30, 2026, including 1.0 million SOL delegated by third parties.
  • Achieved an average net staking yield of 5.9% APY on treasury holdings, outperforming the Solana network average of approximately 4.9% APY by 100 basis points.
  • Held approximately 2.4 million SOL across all categories, with a fair value of approximately $288.2 million as of September 30, 2026.
  • Diluted share count on a Treasury Stock Method basis was approximately 85.2 million shares which equates to 0.0274 SOL per Treasury Stock Method diluted shares
  • Participated in Solana’s first onchain governance vote, publishing the Company’s positions in advance so that delegators could vote with full knowledge of their operator’s view.
  • Delivered over 40 institutional education sessions and advisory workshops with banks, asset managers and exchanges across Asia-Pacific.

Joseph Chee, Chairman, President, and Chief Executive Officer of Solana Company, said:

“This was a milestone quarter for Solana Company. Our Pacific Backbone infrastructure went live, institutions entrusted us with a million SOL of third-party stake, and that confidence is already flowing through to our revenue. Every turn of our flywheel is now picking up speed. We are building the bridge that brings Asia’s financial institutions onto Solana, and with our new headquarters in Hong Kong, we will be building it right where the demand is. We could not be more excited about the road ahead.”

Cosmo Jiang, General Partner at Pantera Capital and board director at Solana Company, said:

“The third quarter showed exactly what sets Solana Company apart. We beat the network’s staking yield by a full percentage point, and put both sides of our capital toolkit to work, buying back shares below NAV and raising capital above it. Owning SOL is a great start. Owning a company that keeps adding more SOL behind every share is even better, and that is the opportunity we are delivering for our shareholders.”

Third Quarter Financial Highlights

  • Generated $3.4 million in revenue, driven primarily by staking revenue on the Company’s SOL holdings, bringing year-to-date revenue to $9.5 million.
  • Earned 30.8 thousand SOL in staking rewards, which were automatically restaked to compound returns.
  • Repurchased approximately $2.8 million of Class A common stock (1.4 million shares) during the quarter, bringing year-to-date repurchases to approximately $8.7 million.

Third Quarter 2026 Financial Results

Revenue for the third quarter of 2026 was $3.4 million, consisting of $3.3 million in staking revenue and $23 thousand of other revenue. This represents significant growth from the $0.7 million in the prior-year period.

Cost of revenue for the third quarter of 2026 was $0.6 million, resulting in gross profit of $2.7 million, or a gross margin of approximately 82%, compared to a gross profit of $0.6 million in the prior-year period.

General and administrative expenses for the third quarter of 2026 were $3.4 million, compared with $5.5 million in the prior-year period. The decrease was primarily due to lower bonus expense and professional fees, partially offset by higher trading advisory and custodian fees, For the first nine months of 2026, general and administrative expenses were $19.7 million, compared with $12.7 million in the prior-year period, primarily due to $6.8 million of severance associated with the PoNS divestiture.

Net operating income for the third quarter of 2026 was $101.1 million, compared with net operating expense of $36.0 million in the prior-year period. The resulting income from operations was $103.9 million, compared with a loss of $35.5 million in the prior-year period, and the loss from operations was $28.4 million for the first nine months of 2026.

Nonoperating income, net, for the third quarter of 2026 was $1.3 million, including a $1.7 million gain from the change in the fair value of the Company’s derivative liability of $1.7 million and other expense of $0.4 million relating primarily to a foreign exchange fluctuations.

Reported net income for the third quarter of 2026 was $105.2 million, or earnings of $1.21 per basic and $1.17 per diluted common share, compared with a net loss of $352.8 million, or a loss of $32.89 per basic and diluted common share, in the prior-year period.

Cash and Liquidity

At September 30, 2026, total assets were $292.6 million, including cash and cash equivalents of $1.1 million, current digital assets of $21.0 million and a $14.8 million digital assets receivable from broker for SOL purchased on September 30, 2026 and settled on October 1, 2026, and $252.4 million of long-term digital assets and digital asset exposure across staked positions, restricted assets, receivables and fund investments. Common shares issued totaled 65.1 million, including 3.1 million shares subject to possible redemption; 57.1 million shares were outstanding as of September 30, 2026, excluding mezzanine shares and net of 4.4 million treasury stock.

About Solana Company

Solana Company (Nasdaq: HSDT) is a publicly listed digital asset treasury and infrastructure company purpose-built to maximize SOL per share. The company combines active treasury management, institutional-grade staking and validator operations with bespoke advisory services for financial institutions navigating blockchain adoption. Solana Company executes a self-reinforcing flywheel designed to compound value with every turn. The company’s mission is to put more SOL behind every share, bridging public capital markets with the most commercially viable blockchain for institutions and financial applications. Visit https://www.solanacompany.co/ for more information.

Forward Looking Statements

This press release contains statements that constitute “forward-looking statements” within the meaning of the U.S. federal securities laws. In some cases, you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict”, “potential” or “continue”, the negative of such terms or other comparable terminology. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. Forward-looking statements may include, among others, statements in relation to the expected benefits and implementation of the Company’s digital asset treasury strategy, the build-out of the Company’s validator infrastructure and advisory businesses, the expected timing and amount of validator rewards, the conversion of the Company’s advisory and third-party staking pipelines, the expected benefits of the divestiture of the Company’s legacy PoNS business, the expected benefits of the Company’s strategic partnerships and collaborations, and the Company’s future growth and operational progress.

These forward-looking statements are based on current expectations, estimates, assumptions, and projections, and involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control, that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. Important factors that may affect actual results include, among others, capital requirements to achieve the Company’s business objectives; expected benefits and implementation of the Company’s digital asset treasury strategy, validator infrastructure and advisory business, strategic partnerships and collaborations, expected staking, yield and broader opportunities across the Solana ecosystem; the Company’s expected token treasury growth; the impact on the Company of global macroeconomic conditions including risks related to logistics challenges, labor shortages, disruptions in the banking system and financial markets; high levels of inflation and high interest rates on the Company’s ability to operate its business and access capital markets; the success of the Company’s business plan; the Company’s operating costs and use of cash; the Company’s ability to achieve significant revenues; and other risks and uncertainties described under “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and in other subsequent filings with the SEC, including its upcoming Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. These filings are available at www.sec.gov. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Media Contact
M Group Strategic Communications (on behalf of Solana Company)
solanaco@mgroupsc.com

Solana Company
Unaudited Condensed Consolidated Balance Sheets
(in thousands, except share and per share data)

  September 30, 2026   December 31, 2025
  (unaudited)    
ASSETS      
Current assets      
Cash and cash equivalents $ 1,129     $ 7,282  
Digital assets   21,000       21,000  
Digital assets collateral receivable   —       —  
Digital assets receivable from broker   14,791       —  
Prepaid expenses and other current assets   1,727       2,873  
Total current assets   38,647       31,155  
Digital assets   190,103       196,724  
Digital assets, restricted   40,237       39,219  
Digital assets receivable   18,743       31,139  
Digital assets fund investment   3,352       5,617  
Other long-term assets   1,566       75  
Total assets $ 292,648     $ 303,929  
LIABILITIES, MEZZANINE AND STOCKHOLDERS’ EQUITY      
Current liabilities      
Accounts payable $ 766       1,890  
Accrued and other current liabilities   849       1,126  
Due to broker   15,000       —  
Total current liabilities   16,615       3,016  
Derivative liability   2,466       —  
Total liabilities   19,081       3,016  
Mezzanine equity      
Class A ordinary common stock subject to possible redemption, $0.001 par value; 3,674,008 and 0 shares at $2 and $0 per share as of September 30, 2026 and December 31, 2025, respectively   7,332       —  
Stockholders’ equity      
Class A ordinary common stock, $0.001 par value; 800,000,000 shares authorized; 61,438,645 shares issued and 57,061,210 outstanding and 43,744,207 shares issued and outstanding as of September 30, 2026 and December 31, 2025 (excluding 3,674,008 and zero ordinary shares subject to possible redemption as of September 30, 2026 and December 31, 2025), respectively   61       44  
Additional paid-in capital   514,409       513,719  
Treasury stock, at cost   (8,677 )     —  
Accumulated deficit   (239,744 )     (212,589 )
Accumulated other comprehensive income (loss)   186       (261 )
Total stockholders’ equity   266,235       300,913  
Total liabilities, mezzanine and stockholders’ equity $ 292,648     $ 303,929  
               

Solana Company
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
(in thousands, except share and per share data)

  Three Months Ended
September 30,
  Nine Months Ended
September 30,
    2026       2025       2026       2025  
Revenue              
Staking revenue $ 3,337     $ 342     $ 9,266     $ 342  
Other revenue   23       355       241       447  
Total revenue   3,360       697       9,507       789  
Cost of revenue   617       103       874       320  
Gross profit   2,743       594       8,633       469  
Operating (income) expenses              
General and administrative expenses   3,386       5,504       19,691       12,714  
Unrealized (gain) loss on digital assets and digital assets receivable   (102,720 )     30,540       (15,885 )     30,540  
Realized loss on digital assets   1,090       —       33,466       —  
Unrealized (gain) loss on digital assets fund investment   (1,335 )     —       648       —  
Gain on digital asset derivatives   (1,528 )     —       (846 )     —  
Net operating (income) expenses   (101,107 )     36,044       37,074       43,254  
Income (loss) from operations   103,850       (35,450 )     (28,441 )     (42,785 )
Nonoperating income (expense)              
Change in fair value of derivative liability   1,741       423,313       1,419       417,394  
Loss on derivative liability   —       (545,733 )     —       (545,733 )
Gain on sale of business   —       —       3,065       —  
Other (expense) income, net   (429 )     (155 )     (869 )     (132 )
Financing costs   —       (194,743 )     (67 )     (195,185 )
Nonoperating income (expense), net   1,312       (317,318 )     3,548       (323,656 )
Income (loss) before provision for income taxes   105,162       (352,768 )     (24,893 )     (366,441 )
Provision for income taxes   —       —       —       —  
Net income (loss)   105,162       (352,768 )     (24,893 )     (366,441 )
Other comprehensive income (loss)              
Foreign currency translation adjustments   (41 )     235       447       (393 )
Comprehensive income (loss) $ 105,121     $ (352,533 )   $ (24,446 )   $ (366,834 )
Earnings (loss) per share              
Basic $ 1.21     $ (32.89 )   $ (0.32 )   $ (90.14 )
Diluted $ 1.17     $ (32.89 )   $ (0.32 )   $ (90.14 )
Weighted average number of common shares outstanding              
Basic   85,021,721       10,724,112       84,291,170       4,065,144  
Diluted   86,305,679       10,724,112       84,291,170       4,065,144  
                               

ATHENS, Greece, Nov. 11, 2026 (GLOBE NEWSWIRE) — Okeanis Eco Tankers Corp. (“OET” or the “Company”) (NYSE: ECO / OSE: OET), announced today that the Company’s board of directors (the “Board”) has declared a dividend on its common shares (the “Dividend”).

Due to implementation of the Central Securities Depository Regulation (“CSDR”) in Norway, shareholders who hold common shares registered in Euronext Securities Oslo (“VPS”), Norway’s central securities depository, should please note the information on the payment date to the common shares registered in VPS below.

The New York Stock Exchange (“NYSE”) settles its trades on a T+1 basis, while the Oslo Stock Exchange (“OSE”) settles its trades on a T+2 basis. As a result, there will be different ex-dividend dates between the two exchanges, as set out below.

Key information relating to the Dividend:

  • Dividend amount: USD 7.00 per common share.
  • Declared currency: USD. Dividends payable to common shares registered in the Euronext VPS will be distributed in NOK.
  • Date of Board approval: November 11, 2026.
  • Last day including right OSE: November 19, 2026, the last date on which the Company’s common shares trading on the OSE will include the entitlement to the Dividend.
  • Last day including right NYSE: November 20, 2026, the last date on which the Company’s common shares trading on the NYSE will include the entitlement to the Dividend.
  • Ex-date OSE: November 20, 2026, the date on which the Company’s common shares will begin trading on the OSE without the entitlement to the Dividend.
  • Ex-date NYSE: November 23, 2026, the date on which the Company’s common shares will begin trading on the NYSE without the entitlement to the Dividend.
  • Record date OSE and NYSE: November 23, 2026
  • Payment date: December 1, 2026. Due to the implementation of CSDR in Norway, the Dividend payable on common shares that are registered in the Euronext VPS is expected to be distributed to Euronext VPS shareholders on or about December 4, 2026.

The Company encourages you to contact your bank, broker, nominee or other institution if you have any questions regarding the mechanics and timing of having the Dividend attributable to your common shares credited to your account.

Contacts

Company:
Iraklis Sbarounis, CFO
Tel: +30 210 480 4200
ir@okeanisecotankers.com

Investor Relations / Media Contact:
Nicolas Bornozis, President
Capital Link, Inc.
230 Park Avenue, Suite 1540, New York, N.Y. 10169
Tel: +1 (212) 661-7566
okeanisecotankers@capitallink.com

About OET
OET is a leading international tanker company providing seaborne transportation of crude oil and refined products. The Company was incorporated on April 30, 2018 under the laws of the Republic of the Marshall Islands and is listed on Oslo Stock Exchange under the symbol OET and the New York Stock Exchange under the symbol ECO. The sailing fleet consists of ten modern scrubber-fitted Suezmax tankers and eight modern scrubber-fitted VLCC tankers.

Forward Looking Statements
This communication contains “forward-looking statements”, including as defined under U.S. federal securities laws. Forward-looking statements provide the Company’s current expectations or forecasts of future events. Forward-looking statements include statements about the Company’s expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts or that are not present facts or conditions. Words or phrases such as “anticipate,” “believe,” “continue,” “estimate,” “expect,” “hope,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will” or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. The Company’s actual results could differ materially from those anticipated in forward-looking statements for many reasons, including as described in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”). Accordingly, you should not unduly rely on these forward-looking statements, which speak only as of the date of this communication. Factors that could cause actual results to differ materially include, but are not limited to, the Company’s operating or financial results; the Company’s liquidity, including its ability to service its indebtedness; competitive factors in the market in which the Company operates; shipping industry trends, including charter rates, vessel values and factors affecting vessel supply and demand; future, pending or recent acquisitions and dispositions, business strategy, areas of possible expansion or contraction, and expected capital spending or operating expenses; risks associated with operations; broader market impacts arising from war (or threatened war) or international hostilities; risks associated with pandemics, including effects on demand for oil and other products transported by tankers and the transportation thereof; and other factors listed from time to time in the Company’s filings with the SEC. Except to the extent required by law, the Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based. You should, however, review the factors and risks the Company describes in the reports it files and furnishes from time to time with the SEC, which can be obtained free of charge on the SEC’s website at www.sec.gov.

This information is published in accordance with the requirements of the Continuing Obligations.

REYKJAVIK, Iceland, Nov. 11, 2026 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced financial results for the nine months to September 30, 2026, and provided a business update.

Supplemental information, including the management presentation providing additional details and a business update, is available on our website: https://alvotech.com/financials.1

Financial Highlights for the Nine Months to September 30, 20262

  • Adjusted total revenue2 was $323.4 million compared to $420.0 million in the same period last year.
  • Gross Margin was 54% compared to 59% in the same period last year.
  • Adjusted EBITDA2 was $78.3 million compared to $68.0 million in the same period last year.
  • Reported cash balance at the end of the period was $61.5 million compared to $172.4 million on December 31, 2025.
    9M 2026     9M 2025     Change   3Q 2026     3Q 2025     Change
Product and Service Revenue   164.2     237.4     -30.8%   58.2     32.6     78.3%
License and Other Revenue   158.9     182.4     -12.9%   53.2     81.1     -34.4%
Other Income   0.4     0.3     45.2%   0.2     0.1     39.8%
Total revenue   323.4     420.0     -23.0%   111.6     113.9     -2.0%
Gross margin   54%     59%         54%     69%      
Adjusted EBITDA   78.3     68.0     15.1%   31.5     14.4     118.8%


Recent Business Highlights

  • The FDA accepted Alvotech’s Biologics License Application (BLA) for AVT80, a proposed biosimilar to Entyvio® (vedolizumab) in prefilled syringe and autoinjector presentations for subcutaneous administration. Alvotech is responsible for development and manufacturing, while Teva has licensed the U.S. commercial rights.
  • Alvotech and its commercial partner Advanz Pharma submitted the first known regulatory submission worldwide for a proposed biosimilar to Eylea HD (aflibercept 8 mg). The marketing application was submitted to the European Medicines Agency.
  • Alvotech signed an agreement with Lotus Pharmaceuticals covering the commercialization rights in the U.S. and selected Asian markets for AVT34, a proposed biosimilar to Imfinzi® (durvalumab) and AVT87, a proposed biosimilar to Hemlibra® (emicizumab). Alvotech retains the right to also commercialize both products directly in the U.S. alongside Lotus.
  • Alvotech and LOTTE Biologics entered a long-term partnership under which LOTTE biologics will manufacture drug substance for multiple biosimilars at its facility in Syracuse, New York. The arrangement expands Alvotech’s U.S. manufacturing footprint, adding additional capacity and flexibility to its global supply network.
  • The U.S. Food and Drug Administration (FDA) approved a new process for manufacturing Simlandi®, Alvotech’s biosimilar to Humira®, in the Reykjavik manufacturing facility. The new process more than doubles output per batch, allowing the same quantity of Simlandi to be produced in fewer batches and thus freeing up manufacturing capacity for other products.
  • The FDA also approved the production of drug substance for Simlandi® in a second production suite at Alvotech’s Reykjavik site, resulting in added flexibility and increased manufacturing capacity.

Lisa Graver, Chief Executive Officer, comments:

“Our commercial performance strengthened in the third quarter, with product and service revenue reaching $58 million, up 6% sequentially and 78% year over year. Following the completion of the manufacturing improvement program in the first half of the year, we are continuing to increase supply to meet strong underlying demand across our markets.

“The two recent FDA approvals for Simlandi at our Reykjavík facility represent significant milestones. The addition of a second approved manufacturing suite and an enhanced process that more than doubles output per batch give us greater capacity and operational flexibility to support our expanding commercial portfolio.

“We have also made important advances in our pipeline, including regulatory milestones for our proposed biosimilars to Entyvio and high-dose Eylea. Our agreement with Lotus creates an opportunity for Alvotech to participate directly in U.S. commercialization, while our partnerships with LOTTE Biologics and Fujifilm strengthen our future manufacturing network. Our priority now is to translate this progress into planned product deliveries in the fourth quarter, while continuing to build the platform for long-term growth.”

Outlook for the Full Year 2026

Alvotech maintains its full-year 2026 guidance for total revenue of $650-$700 million and EBITDA of $180-$220 million, with performance now expected toward the lower end of the range. The Company remains focused on executing planned product deliveries in the fourth quarter, as production and commercial supply continue to ramp up following the manufacturing improvement program completed in the first half of the year.

Invitation to management presentation

Join us to listen to the live audio webcast at 8:00 AM EST (13:00 GMT, 14:00 CET) on Thursday, November 12, 2026. Materials for the webcast are available at https://alvotech.com/financials.

The audio webcast will be accessible via the following link:
https://edge.media-server.com/mmc/p/xog3u2xy

To participate via telephone in the Q&A session, register using this link:
https://register-conf.media-server.com/register/BIc6f9e20f129b4e789c7bc1a732488c5c

Contacts

Media contacts – alvotech.media@alvotech.com
Benedikt Stefansson
Sarah MacLeod

Investor Relations contacts – alvotech.ir@alvotech.com
Dr. Balaji V Prasad
Benedikt Stefansson
Mikaela Vilchez

Financial calendar

Annual or interim results will be released on the dates specified below, after the close of U.S. markets. An earnings call is held on the following day, after release of the results. Please note that all dates are subject to change.

Quarter Date of release Date of earnings call
Q4 2026  March 10, 2027 March 11, 2027


Upcoming events

Alvotech’s management team will appear at several investor conferences in November 2026. Please visit our events page https://alvotech.com/events to find more information about the timing of these events and how to register for live webcasts. Please note that all details are subject to change.

Date Event Location
Tuesday, November 17, 2026 UBS Global Biopharma Conference London
Wednesday, November 18, 2026 Jefferies Global Healthcare Conference London
Tuesday, November 24, 2026 DNB Carnegie Healthcare Conference Oslo
Wednesday, November 25, 2026 SEB Healthcare Seminar Stockholm


About Alvotech 

Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.

For more information, please visit our website or follow us on social media on LinkedIn, Facebook, Instagram, and YouTube.

Forward Looking Statements

Certain statements in this communication may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, for example, Alvotech’s expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, market launches and financial projections. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to factors set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in documents that Alvotech may from time-to-time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed.

Non IFRS Financial Measures

This Presentation may include projections of certain financial measures not presented in accordance with International Financial Reporting Standards (“IFRS”) including, but not limited to, Adjusted Revenues, EBITDA and certain ratios and other metrics derived therefrom. These non-IFRS financial measures are not measures of financial performance in accordance with IFRS and may exclude items that are significant in understanding and assessing the Company’s financial results. Therefore, these measures should not be considered in isolation or as an alternative to net income, cash flows from operations or other measures of profitability, liquidity or performance under IFRS. You should be aware that the Company’s presentation of these measures may not be comparable to similarly-titled measures used by other companies. The Company believes these non-IFRS measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to the Company’s financial condition and results of operations. The Company believes that the use of these non-IFRS financial measures provide an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing the Company’s financial measures with other similar companies, many of which present similar non-IFRS financial measures to investors. These non-IFRS financial measures are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and income are excluded or included in determining these non-IFRS financial measures. Due to the high variability and difficulty in making accurate forecasts and projections of some of the information excluded from these projected measures, together with some of the excluded information not being ascertainable or accessible, the Company is unable to quantify certain amounts that would be required to be included in the most directly comparable IFRS financial measures without unreasonable effort. Consequently, no disclosure of estimated comparable IFRS measures is included and no reconciliation of the forward-looking non-IFRS financial measures is included. For the same reasons, the Company is unable to address the probable significance of the unavailable information, which could be material to future results.

Reported to Adjusted Reconciliation for the nine months ended September 30, 2026 and 2025
 
  2026 9M   2025 9M
USD millions Reported Adjustment Adjusted   Reported Adjustment Adjusted
Product and Service Revenue 164.2 – 164.2   237.4 – 237.4
License and Other Revenue 158.9 – 158.9   182.4 0.3 182.6
Other Income 0.4 – 0.4   0.3 (0.3) –
Total revenue 323.4 – 323.4   420.0 – 420.0
Cost of Product Revenue (150.1) 1.1 (149.0)   (174.3) 1.4 (172.9)
R&D (63.6) (0.5) (64.1)   (144.5) (7.6) (152.1)
G&A (98.9) 35.0 (63.9)   (71.3) 16.8 (54.5)
Operating Profit (Loss) 10.8 35.6 46.3   30.0 10.7 40.6
D&A (32.0) – (32.0)   (27.4) 0.0 (27.4)
EBITDA 42.8 35.6 78.3   57.4 10.7 68.0

Reported to Adjusted Reconciliation for the quarters ended September 30, 2026 and 2025
 
  2026 3Q   2025 3Q
USD millions Reported Adjustment Adjusted   Reported Adjustment Adjusted
Product and Service Revenue 58.2 – 58.2   32.6 – 32.6
License and Other Revenue 53.2 – 53.2   81.1 – 81.1
Other Income 0.2 – 0.2   0.1 – 0.1
Total revenue 111.6 – 111.6   113.9 – 113.9
Cost of Product Revenue (51.8) 0.2 (51.6)   (35.0) 0.1 (34.9)
R&D (17.2) 0.2 (17.0)   (51.6) (3.5) (55.1)
G&A (29.7) 6.9 (22.8)   (25.9) 6.2 (19.8)
Operating Profit (Loss) 12.8 7.3 20.1   1.3 2.8 4.1
D&A (11.4) – (11.4)   (10.3) 0.0 (10.3)
EBITDA 24.2 7.3 31.5   11.6 2.8 14.4

Unaudited Condensed Consolidated Interim Statements of Profit or Loss and Other Comprehensive Income or Loss for the nine months ended September 30, 2026 and 2025
USD in thousands, except for per share amounts   Nine months ended
September 30,
2026
  Nine months ended
September 30,
2025
Product and service revenue   164,152   237,382
License and other revenue   158,883   182,366
Other income   379   261
Cost of product and service revenue   (150,103)   (174,278)
Research and development expenses   (63,613)   (144,508)
General and administrative expenses   (98,919)   (71,271)
Operating profit   10,779   29,952
Effects resulting from business combination   —   7,977
Finance income   8,980   170,687
Finance costs   (168,684)   (108,449)
Exchange rate differences   (5,280)   (21,226)
Net gain on modification and extinguishment of financial liabilities   —   17,703
Non-operating (loss) / profit   (164,984)   66,692
(Loss) / profit before taxes   (154,205)   96,644
Income tax benefit   13,546   39,822
(Loss) / profit for the period   (140,659)   136,466
Other comprehensive (loss) / profit        
Item that will be reclassified to profit or loss in subsequent periods:        
Exchange rate differences on translation of foreign operations   (2,794)   3,310
Total comprehensive (loss) /profit   (143,453)   139,776
(Loss) / profit per share        
Basic (loss) / profit for the period per share   (0.45)   0.47
Diluted (loss) / profit for the period per share   (0.45)   0.47

Unaudited Condensed Consolidated Interim Statements of Financial Position as of September 30, 2026 and December 31, 2025
USD in thousands        
Non-current assets   September 30   December 31
2026 2025
Property, plant and equipment   367,141   356,398
Right-of-use assets   145,349   138,294
Goodwill   12,377   12,835
Other intangible assets   174,340   81,834
Contract assets   177,885   122,934
Other long-term assets   18,200   8,578
Deferred tax assets   208,038   192,211
Total non-current assets   1,103,330   913,084
Current assets        
Inventories   242,252   220,054
Trade receivables   65,179   69,740
Contract assets   54,978   64,440
Other current assets   83,584   46,984
Receivables from related parties   5,252   438
Cash and cash equivalents   61,468   172,359
Total current assets   512,713   574,015
Total assets   1,616,043   1,487,099

Unaudited Condensed Consolidated Interim Statements of Financial Position as of September 30, 2026 and December 31, 2025
USD in thousands        
Equity   September 30   December 31
2026 2025
Share capital   3,380   2,929
Share premium   2,269,996   2,105,691
Other reserves   11,248   15,331
Translation reserve   (1,442)   1,352
Accumulated deficit   (2,550,449)   (2,409,790)
Total equity   (267,267)   (284,487)
Non-current liabilities        
Borrowings   1,341,286   1,262,147
Derivative financial liabilities   90,540   53,994
Lease liabilities   151,559   137,999
Contract liabilities   4,184   5,500
Deferred tax liability   7,943   7,868
Total non-current liabilities   1,595,512   1,467,508
Current liabilities        
Trade and other payables   90,214   126,124
Lease liabilities   12,969   12,078
Current maturities of borrowings   54,967   36,921
Liabilities to related parties   3,368   3,325
Contract liabilities   3,742   30,364
Taxes payable   2,014   1,041
Other current liabilities   120,524   94,225
Total current liabilities   287,798   304,078
Total liabilities   1,883,310   1,771,586
Total equity and liabilities   1,616,043   1,487,099

Unaudited Condensed Consolidated Interim Statements of Cash Flows for the nine months ended September 30, 2026 and 2025
USD in thousands        
Cash flows from operating activities   Nine months ended
September 30, 2026
  Nine months ended
September 30, 2025
(Loss) / profit for the period   (140,659)   136,466
Adjustments for non-cash items:        
Depreciation, amortization and impairment   31,976   27,438
Effects resulting from business combination   —   (7,977)
Change in allowance for receivables   569   703
Change in inventory reserves   5,707   8,713
Share-based payments   7,094   6,166
Change in commercial provision   20,200   —
Net gain on modification and extinguishment of financial liabilities   —   (17,703)
Finance income   (8,980)   (170,687)
Finance costs   168,684   108,449
Exchange rate difference   5,280   21,226
Income tax benefit   (13,546)   (39,822)
Operating cash flow before movement in working capital   76,325   72,972
Increase in inventories   (27,905)   (85,871)
Decrease in trade receivables   3,992   100,235
Increase in receivables with related parties   (4,814)   (882)
Increase in contract assets   (46,649)   (29,333)
Increase in other assets   (37,673)   (8,169)
(Decrease) / increase in trade and other payables   (35,446)   25,092
Decrease in contract liabilities   (27,324)   (49,694)
Increase / (decrease) in liabilities with related parties   43   (1,205)
Increase in other liabilities   2,840   12,070
Cash (used in) / from operations   (96,611)   35,215
Interest received   806   294
Interest paid   (109,061)   (22,338)
Income tax paid   (746)   (455)
Net cash (used in) / from operating activities   (205,612)   12,716

Unaudited Condensed Consolidated Interim Statements of Cash Flows for the nine months ended September 30, 2026 and 2025
USD in thousands   Nine months ended
September 30, 2026
  Nine months ended
September 30, 2025
Cash flows from investing activities        
Acquisition of property, plant and equipment   (40,357)   (55,731)
Acquisition of intangible assets   (88,164)   (24,632)
Net cash outflow on acquisition of subsidiary   —   (14,036)
Proceeds from the sale in joint venture   —   5,950
Net cash used in investing activities   (128,521)   (88,449)
Cash flows from financing activities        
Repayments of borrowings   (33,585)   (18,402)
Repayments of principal portion of lease liabilities   (9,274)   (8,285)
Proceeds from new borrowings   113,676   12,028
Transaction cost from new borrowings   (2,811)   —
Gross proceeds from equity offering   164,600   82,481
Fees from equity offering   (8,521)   (3,759)
Net cash from financing activities   224,085   64,063
Decrease in cash and cash equivalents   (110,048)   (11,670)
Cash and cash equivalents at the beginning of the period   172,359   51,428
Effect of movements in exchange rates on cash held   (843)   3,090
Cash and cash equivalents at the end of the period   61,468   42,848
         

______________________________ 
1
Supplemental information, including the management presentation, is provided solely for reference and is not part of this SEC form 6‑K and the form 6‑K should not be read together with, or construed as referring to, the supplemental information.
2 Unless otherwise specified, all figures presented in the Financial Highlights are on an adjusted basis and exclude items that are not indicative of our ongoing operating performance. See the tables on ‘Reported to Adjusted Reconciliation’ and disclaimer on ‘Non IFRS Financial Measures’, at the end of this press release. As a foreign private issuer, Alvotech is not required to, and does not, prepare or file quarterly financial statements under IFRS or with the SEC. The financial information included in this Form 6-K reflects management’s current estimates and is presented for the purpose of providing an interim business update.

REYKJAVIK, ICELAND (November 11, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced financial results for the nine months to September 30, 2026, and provided a business update.

Supplemental information, including the management presentation providing additional details and a business update, is available on our website: https://alvotech.com/financials.1

Financial Highlights for the Nine Months to September 30, 20262

  • Adjusted total revenue2 was $323.4 million compared to $420.0 million in the same period last year.
  • Gross Margin was 54% compared to 59% in the same period last year.
  • Adjusted EBITDA2 was $78.3 million compared to $68.0 million in the same period last year.
  • Reported cash balance at the end of the period was $61.5 million compared to $172.4 million on December 31, 2025.
    9M 2026   9M 2025   Change   3Q 2026   3Q 2025   Change
Product and Service Revenue   164.2   237.4   -30.8%   58.2   32.6   78.3%
License and Other Revenue   158.9   182.4   -12.9%   53.2   81.1   -34.4%
Other Income   0.4   0.3   45.2%   0.2   0.1   39.8%
Total revenue   323.4   420.0   -23.0%   111.6   113.9   -2.0%
Gross margin   54%   59%       54%   69%    
Adjusted EBITDA   78.3   68.0   15.1%   31.5   14.4   118.8%

Recent Business Highlights

  • The FDA accepted Alvotech’s Biologics License Application (BLA) for AVT80, a proposed biosimilar to Entyvio® (vedolizumab) in prefilled syringe and autoinjector presentations for subcutaneous administration. Alvotech is responsible for development and manufacturing, while Teva has licensed the U.S. commercial rights.
  • Alvotech and its commercial partner Advanz Pharma submitted the first known regulatory submission worldwide for a proposed biosimilar to Eylea HD (aflibercept 8 mg). The marketing application was submitted to the European Medicines Agency.
  • Alvotech signed an agreement with Lotus Pharmaceuticals covering the commercialization rights in the U.S. and selected Asian markets for AVT34, a proposed biosimilar to Imfinzi® (durvalumab) and AVT87, a proposed biosimilar to Hemlibra® (emicizumab). Alvotech retains the right to also commercialize both products directly in the U.S. alongside Lotus.
  • Alvotech and LOTTE Biologics entered a long-term partnership under which LOTTE biologics will manufacture drug substance for multiple biosimilars at its facility in Syracuse, New York. The arrangement expands Alvotech’s U.S. manufacturing footprint, adding additional capacity and flexibility to its global supply network.
  • The U.S. Food and Drug Administration (FDA) approved a new process for manufacturing Simlandi®, Alvotech’s biosimilar to Humira®, in the Reykjavik manufacturing facility. The new process more than doubles output per batch, allowing the same quantity of Simlandi to be produced in fewer batches and thus freeing up manufacturing capacity for other products.
  • The FDA also approved the production of drug substance for Simlandi® in a second production suite at Alvotech’s Reykjavik site, resulting in added flexibility and increased manufacturing capacity.

Lisa Graver, Chief Executive Officer, comments:

“Our commercial performance strengthened in the third quarter, with product and service revenue reaching $58 million, up 6% sequentially and 78% year over year. Following the completion of the manufacturing improvement program in the first half of the year, we are continuing to increase supply to meet strong underlying demand across our markets.

“The two recent FDA approvals for Simlandi at our Reykjavík facility represent significant milestones. The addition of a second approved manufacturing suite and an enhanced process that more than doubles output per batch give us greater capacity and operational flexibility to support our expanding commercial portfolio.

“We have also made important advances in our pipeline, including regulatory milestones for our proposed biosimilars to Entyvio and high-dose Eylea. Our agreement with Lotus creates an opportunity for Alvotech to participate directly in U.S. commercialization, while our partnerships with LOTTE Biologics and Fujifilm strengthen our future manufacturing network. Our priority now is to translate this progress into planned product deliveries in the fourth quarter, while continuing to build the platform for long-term growth.”

Outlook for the Full Year 2026

Alvotech maintains its full-year 2026 guidance for total revenue of $650-$700 million and EBITDA of $180-$220 million, with performance now expected toward the lower end of the range. The Company remains focused on executing planned product deliveries in the fourth quarter, as production and commercial supply continue to ramp up following the manufacturing improvement program completed in the first half of the year.

Invitation to management presentation

Join us to listen to the live audio webcast at 8:00 AM EST (13:00 GMT, 14:00 CET) on Thursday, November 12, 2026. Materials for the webcast are available at https://alvotech.com/financials.

The audio webcast will be accessible via the following link:
https://edge.media-server.com/mmc/p/xog3u2xy

To participate via telephone in the Q&A session, register using this link:
https://register-conf.media-server.com/register/BIc6f9e20f129b4e789c7bc1a732488c5c

Contacts

Media contacts – alvotech.media@alvotech.com
Benedikt Stefansson
Sarah MacLeod

Investor Relations contacts – alvotech.ir@alvotech.com
Dr. Balaji V Prasad
Benedikt Stefansson
Mikaela Vilchez

Financial calendar

Annual or interim results will be released on the dates specified below, after the close of U.S. markets. An earnings call is held on the following day, after release of the results. Please note that all dates are subject to change.

Quarter Date of release Date of earnings call
Q4 2026 March 10, 2027 March 11, 2027

Upcoming events

Alvotech’s management team will appear at several investor conferences in November 2026. Please visit our events page https://alvotech.com/events to find more information about the timing of these events and how to register for live webcasts. Please note that all details are subject to change.

Date Event Location
Tuesday, November 17, 2026 UBS Global Biopharma Conference London
Wednesday, November 18, 2026 Jefferies Global Healthcare Conference London
Tuesday, November 24, 2026 DNB Carnegie Healthcare Conference Oslo
Wednesday, November 25, 2026 SEB Healthcare Seminar Stockholm

About Alvotech

Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.

For more information, please visit our  website or follow us on social media on LinkedIn, Facebook, Instagram, and YouTube.

Forward Looking Statements

Certain statements in this communication may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, for example, Alvotech’s expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, market launches and financial projections. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to factors set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in documents that Alvotech may from time-to-time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed.

Non IFRS Financial Measures

This Presentation may include projections of certain financial measures not presented in accordance with International Financial Reporting Standards (“IFRS”) including, but not limited to, Adjusted Revenues, EBITDA and certain ratios and other metrics derived therefrom. These non-IFRS financial measures are not measures of financial performance in accordance with IFRS and may exclude items that are significant in understanding and assessing the Company’s financial results. Therefore, these measures should not be considered in isolation or as an alternative to net income, cash flows from operations or other measures of profitability, liquidity or performance under IFRS. You should be aware that the Company’s presentation of these measures may not be comparable to similarly-titled measures used by other companies. The Company believes these non-IFRS measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to the Company’s financial condition and results of operations. The Company believes that the use of these non-IFRS financial measures provide an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing the Company’s financial measures with other similar companies, many of which present similar non-IFRS financial measures to investors. These non-IFRS financial measures are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and income are excluded or included in determining these non-IFRS financial measures. Due to the high variability and difficulty in making accurate forecasts and projections of some of the information excluded from these projected measures, together with some of the excluded information not being ascertainable or accessible, the Company is unable to quantify certain amounts that would be required to be included in the most directly comparable IFRS financial measures without unreasonable effort. Consequently, no disclosure of estimated comparable IFRS measures is included and no reconciliation of the forward-looking non-IFRS financial measures is included. For the same reasons, the Company is unable to address the probable significance of the unavailable information, which could be material to future results.

Reported to Adjusted Reconciliation for the nine months ended September 30, 2026 and 2025
    2026 9M       2025 9M  
USD millions Reported Adjustment Adjusted   Reported Adjustment Adjusted
Product and Service Revenue 164.2 – 164.2   237.4 – 237.4
License and Other Revenue 158.9 – 158.9   182.4 0.3 182.6
Other Income 0.4 – 0.4   0.3 (0.3) –
Total revenue 323.4 – 323.4   420.0 – 420.0
Cost of Product Revenue (150.1) 1.1 (149.0)   (174.3) 1.4 (172.9)
R&D (63.6) (0.5) (64.1)   (144.5) (7.6) (152.1)
G&A (98.9) 35.0 (63.9)   (71.3) 16.8 (54.5)
Operating Profit (Loss) 10.8 35.6 46.3   30.0 10.7 40.6
D&A (32.0) – (32.0)   (27.4) 0.0 (27.4)
EBITDA 42.8 35.6 78.3   57.4 10.7 68.0

Reported to Adjusted Reconciliation for the quarters ended September 30, 2026 and 2025
    2026 3Q       2025 3Q  
USD millions Reported Adjustment Adjusted   Reported Adjustment Adjusted
Product and Service Revenue 58.2 – 58.2   32.6 – 32.6
License and Other Revenue 53.2 – 53.2   81.1 – 81.1
Other Income 0.2 – 0.2   0.1 – 0.1
Total revenue 111.6 – 111.6   113.9 – 113.9
Cost of Product Revenue (51.8) 0.2 (51.6)   (35.0) 0.1 (34.9)
R&D (17.2) 0.2 (17.0)   (51.6) (3.5) (55.1)
G&A (29.7) 6.9 (22.8)   (25.9) 6.2 (19.8)
Operating Profit (Loss) 12.8 7.3 20.1   1.3 2.8 4.1
D&A (11.4) – (11.4)   (10.3) 0.0 (10.3)
EBITDA 24.2 7.3 31.5   11.6 2.8 14.4

Unaudited Condensed Consolidated Interim Statements of Profit or Loss and Other Comprehensive Income or Loss for the nine months ended September 30, 2026 and 2025
USD in thousands, except for per share amounts   Nine months ended September 30, 2026   Nine months ended September 30, 2025
Product and service revenue   164,152   237,382
License and other revenue   158,883   182,366
Other income   379   261
Cost of product and service revenue   (150,103)   (174,278)
Research and development expenses   (63,613)   (144,508)
General and administrative expenses   (98,919)   (71,271)
Operating profit   10,779   29,952
Effects resulting from business combination   —   7,977
Finance income   8,980   170,687
Finance costs   (168,684)   (108,449)
Exchange rate differences   (5,280)   (21,226)
Net gain on modification and extinguishment of financial liabilities   —   17,703
Non-operating (loss) / profit   (164,984)   66,692
(Loss) / profit before taxes   (154,205)   96,644
Income tax benefit   13,546   39,822
(Loss) / profit for the period   (140,659)   136,466
Other comprehensive (loss) / profit        
Item that will be reclassified to profit or loss in subsequent periods:        
Exchange rate differences on translation of foreign operations   (2,794)   3,310
Total comprehensive (loss) /profit   (143,453)   139,776
(Loss) / profit per share        
Basic (loss) / profit for the period per share   (0.45)   0.47
Diluted (loss) / profit for the period per share   (0.45)   0.47

Unaudited Condensed Consolidated Interim Statements of Financial Position as of September 30, 2026 and December 31, 2025
USD in thousands        
Non-current assets   September 30   December 31
2026 2025
Property, plant and equipment   367,141   356,398
Right-of-use assets   145,349   138,294
Goodwill   12,377   12,835
Other intangible assets   174,340   81,834
Contract assets   177,885   122,934
Other long-term assets   18,200   8,578
Deferred tax assets   208,038   192,211
Total non-current assets   1,103,330   913,084
Current assets        
Inventories   242,252   220,054
Trade receivables   65,179   69,740
Contract assets   54,978   64,440
Other current assets   83,584   46,984
Receivables from related parties   5,252   438
Cash and cash equivalents   61,468   172,359
Total current assets   512,713   574,015
Total assets   1,616,043   1,487,099
         

Unaudited Condensed Consolidated Interim Statements of Financial Position as of September 30, 2026 and December 31, 2025
USD in thousands        
Equity   September 30   December 31
2026 2025
Share capital   3,380   2,929
Share premium   2,269,996   2,105,691
Other reserves   11,248   15,331
Translation reserve   (1,442)   1,352
Accumulated deficit   (2,550,449)   (2,409,790)
Total equity   (267,267)   (284,487)
Non-current liabilities        
Borrowings   1,341,286   1,262,147
Derivative financial liabilities   90,540   53,994
Lease liabilities   151,559   137,999
Contract liabilities   4,184   5,500
Deferred tax liability   7,943   7,868
Total non-current liabilities   1,595,512   1,467,508
Current liabilities        
Trade and other payables   90,214   126,124
Lease liabilities   12,969   12,078
Current maturities of borrowings   54,967   36,921
Liabilities to related parties   3,368   3,325
Contract liabilities   3,742   30,364
Taxes payable   2,014   1,041
Other current liabilities   120,524   94,225
Total current liabilities   287,798   304,078
Total liabilities   1,883,310   1,771,586
Total equity and liabilities   1,616,043   1,487,099

Unaudited Condensed Consolidated Interim Statements of Cash Flows for the nine months ended September 30, 2026 and 2025
USD in thousands        
Cash flows from operating activities   Nine months ended September 30, 2026   Nine months ended September 30, 2025
(Loss) / profit for the period   (140,659)   136,466
Adjustments for non-cash items:        
Depreciation, amortization and impairment   31,976   27,438
Effects resulting from business combination   —   (7,977)
Change in allowance for receivables   569   703
Change in inventory reserves   5,707   8,713
Share-based payments   7,094   6,166
Change in commercial provision   20,200   —
Net gain on modification and extinguishment of financial liabilities   —   (17,703)
Finance income   (8,980)   (170,687)
Finance costs   168,684   108,449
Exchange rate difference   5,280   21,226
Income tax benefit   (13,546)   (39,822)
Operating cash flow before movement in working capital   76,325   72,972
Increase in inventories   (27,905)   (85,871)
Decrease in trade receivables   3,992   100,235
Increase in receivables with related parties   (4,814)   (882)
Increase in contract assets   (46,649)   (29,333)
Increase in other assets   (37,673)   (8,169)
(Decrease) / increase in trade and other payables   (35,446)   25,092
Decrease in contract liabilities   (27,324)   (49,694)
Increase / (decrease) in liabilities with related parties   43   (1,205)
Increase in other liabilities   2,840   12,070
Cash (used in) / from operations   (96,611)   35,215
Interest received   806   294
Interest paid   (109,061)   (22,338)
Income tax paid   (746)   (455)
Net cash (used in) / from operating activities   (205,612)   12,716
         

Unaudited Condensed Consolidated Interim Statements of Cash Flows for the nine months ended September 30, 2026 and 2025
USD in thousands   Nine months ended September 30, 2026   Nine months ended September 30, 2025
Cash flows from investing activities        
Acquisition of property, plant and equipment   (40,357)   (55,731)
Acquisition of intangible assets   (88,164)   (24,632)
Net cash outflow on acquisition of subsidiary   —   (14,036)
Proceeds from the sale in joint venture   —   5,950
Net cash used in investing activities   (128,521)   (88,449)
Cash flows from financing activities        
Repayments of borrowings   (33,585)   (18,402)
Repayments of principal portion of lease liabilities   (9,274)   (8,285)
Proceeds from new borrowings   113,676   12,028
Transaction cost from new borrowings   (2,811)   —
Gross proceeds from equity offering   164,600   82,481
Fees from equity offering   (8,521)   (3,759)
Net cash from financing activities   224,085   64,063
Decrease in cash and cash equivalents   (110,048)   (11,670)
Cash and cash equivalents at the beginning of the period   172,359   51,428
Effect of movements in exchange rates on cash held   (843)   3,090
Cash and cash equivalents at the end of the period   61,468   42,848


1 Supplemental information, including the management presentation, is provided solely for reference and is not part of this SEC form 6‑K and the form 6‑K should not be read together with, or construed as referring to, the supplemental information.
2 Unless otherwise specified, all figures presented in the Financial Highlights are on an adjusted basis and exclude items that are not indicative of our ongoing operating performance. See the tables on ‘Reported to Adjusted Reconciliation’ and disclaimer on ‘Non IFRS Financial Measures’, at the end of this press release. As a foreign private issuer, Alvotech is not required to, and does not, prepare or file quarterly financial statements under IFRS or with the SEC. The financial information included in this Form 6-K reflects management’s current estimates and is presented for the purpose of providing an interim business update.

ATHENS, Greece, Nov. 11, 2026 (GLOBE NEWSWIRE) — Okeanis Eco Tankers Corp. (together with its subsidiaries, unless context otherwise dictates, “OET” or the “Company”) (NYSE: ECO, OSE: OET) today reported its unaudited condensed financial results for the third quarter and nine-month period of 2026, which are attached to this press release.

Financial performance of the Third Quarter Ended September 30, 2026

  • Revenues of $501.5 million in Q3 2026, compared to $90.6 million in Q3 2025.
  • Profit of $299.6 million in Q3 2026, compared to $24.1 million in Q3 2025.
  • Vessel operating expenses of $14.8 million in Q3 2026, compared to $11.7 million in Q3 2025.
  • Earnings per share of $7.67 in Q3 2026, compared to $0.75 in Q3 2025.
  • Cash (including restricted cash) of $233.1 million as of September 30, 2026, compared to $122.5 million as of December 31, 2025.

Financial performance of the Nine Months Ended September 30, 2026

  • Revenues of $990.5 million in 9M 2026, compared to $264.7 million in 9M 2025.
  • Profit of $618.2 million in 9M 2026, compared to $63.5 million in 9M 2025.
  • Vessel operating expenses of $40.4 million in 9M 2026, compared to $33.8 million in 9M 2025.
  • Earnings per share of $15.95 in 9M 2026, compared to $1.97 in 9M 2025.

Alternative performance metrics and market development

  • Time charter equivalent* (“TCE”, a non-IFRS measure*) revenue of $338.3 million in Q3 2026.
  • EBITDA* and Adjusted EBITDA* (each, a non-IFRS measure*) of $323.1 million and $320.4 million, respectively, in Q3 2026.
  • Adjusted profit* and Adjusted earnings per share* (each, a non-IFRS measure*) of $299.5 million or $7.67 per basic and diluted share in Q3 2026.
  • During Q3 2026, we entered into a series of short-term charter agreements for five of our VLCC vessels, for a period of 100-150 days each, with an average rate of $449,200 per day.
  • In Q3 2026, fleetwide daily TCE rate* of $206,800 per available spot day and $209,100 per operating day; VLCC TCE rate of $269,300 per available spot day and $260,100 per operating day; and Suezmax TCE rate of $166,600 per available spot and operating day.
  • Daily vessel operating expenses* (“Daily Opex”, a non-IFRS measure*) of $9,401 per calendar day, in Q3 2026.
  • In Q4 2026 to date: on the VLCC fleet 48% of the available spot days have been booked at an average TCE rate of $688,800 per day and 87% of operating days have been booked at an average TCE rate of $430,300; on the Suezmax fleet 60% of available spot and operating days have been booked at an average TCE rate of $410,900.

Declaration of Q3 2026 dividend

The Company’s board of directors declared a dividend of $7.00 per common share to shareholders. Dividends payable to common shares registered in the Euronext VPS will be distributed in NOK. The cash payment will be paid on December 1, 2026, to shareholders of record as of November 23, 2026. The common shares will be traded ex-dividend on the NYSE as from and including November 23, 2026, and the common shares will be traded ex-dividend on the Oslo Stock Exchange as from and including November 20, 2026. Due to the implementation of the Central Securities Depository Regulation (CSDR) in Norway, dividends payable on common shares registered with Euronext VPS are expected to be distributed to Euronext VPS shareholders on or about December 4, 2026.

*The Company uses certain financial information calculated on a basis other than in accordance with International Financial Reporting Standards (“IFRS”) and generally accepted accounting principles, including TCE, Daily TCE, EBITDA, Adjusted EBITDA, Adjusted profit, Adjusted earnings per share, and Daily Opex. For a reconciliation of these non-IFRS measures, please refer to the end of this press release.

Presentation

OET will be hosting a conference call and webcast at 14:30 CET on November 12, 2026 to discuss the Q3 2026 and 9M 2026 results.

The webcast will include a slide presentation and will be available on the following link:
https://events.q4inc.com/attendee/254903002

An audio replay of the conference call will be available on our website:
http://www.okeanisecotankers.com/reports/

Information on or accessed through our website is not incorporated herein.

Contacts

Company:
Iraklis Sbarounis, CFO
Tel: +30 210 480 4200
ir@okeanisecotankers.com

Investor Relations / Media Contact:
Nicolas Bornozis, President
Capital Link, Inc.
230 Park Avenue, Suite 1540, New York, N.Y. 10169
Tel: +1 (212) 661-7566
okeanisecotankers@capitallink.com

About OET

OET is a leading international tanker company providing seaborne transportation of crude oil and refined products. The Company was incorporated on April 30, 2018 under the laws of the Republic of the Marshall Islands and is listed on Oslo Stock Exchange under the symbol OET and the New York Stock Exchange under the symbol ECO. The sailing fleet consists of ten modern scrubber-fitted Suezmax tankers and eight modern scrubber-fitted VLCC tankers.

Forward Looking Statements

This communication contains “forward-looking statements”, including as defined under U.S. federal securities laws. Forward-looking statements provide the Company’s current expectations or forecasts of future events. Forward-looking statements include statements about the Company’s expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts or that are not present facts or conditions. Words or phrases such as “anticipate,” “believe,” “continue,” “estimate,” “expect,” “hope,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will” or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. The Company’s actual results could differ materially from those anticipated in forward-looking statements for many reasons, including as described in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”). Accordingly, you should not unduly rely on these forward-looking statements, which speak only as of the date of this communication. Factors that could cause actual results to differ materially include, but are not limited to, the Company’s operating or financial results; the Company’s liquidity, including its ability to service its indebtedness; competitive factors in the market in which the Company operates; shipping industry trends, including charter rates, vessel values and factors affecting vessel supply and demand; future, pending or recent acquisitions and dispositions, business strategy, areas of possible expansion or contraction, and expected capital spending or operating expenses; risks associated with operations; broader market impacts arising from war (or threatened war) or international hostilities; risks associated with pandemics, including effects on demand for oil and other products transported by tankers and the transportation thereof; and other factors listed from time to time in the Company’s filings with the SEC. Except to the extent required by law, the Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based. You should, however, review the factors and risks the Company describes in the reports it files and furnishes from time to time with the SEC, which can be obtained free of charge on the SEC’s website at www.sec.gov.

This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

A PDF associated with this press release can be found here: http://ml.globenewswire.com/Resource/Download/c968da0d-e3cf-4d9a-9205-7c1f518e7469

NEW YORK, Nov. 11, 2026 (GLOBE NEWSWIRE) — StablecoinX Inc. (Nasdaq: USDE), the first public stablecoin infrastructure company focusing on the Ethena digital dollar ecosystem, today announced that it will release its financial results for the third quarter ended September 30, 2026, before the market opens on Monday, November 16, 2026, and host a webcast at 8:30 a.m. Eastern Time the next day, on Tuesday, November 17, 2026.

During the webcast, Christopher Jensen, Chief Executive Officer, Young Cho, Chief Financial Officer, and Edward Chen, Chairman of the Board, will provide a business update, including progress on all three business lines: Infrastructure Services (DVN), Infrastructure Software, and Distribution Services. A live question-and-answer session will follow the prepared remarks.

Webcast Details

The webcast with an accompanying slide presentation can be accessed at: https://edge.media-server.com/mmc/p/zx92vi7c

Investors and analysts may submit questions in advance to ir@stablecoinx.com. The earnings press release and accompanying presentation will be available on the Investor Relations section of the Company’s website at StablecoinX – News.

About StablecoinX

StablecoinX Inc. (Nasdaq: USDE) is a publicly traded company offering investors exposure to the stablecoin economy through its strategic focus on the Ethena ecosystem, one of the world’s largest issuers of digital dollars. The Company operates across infrastructure services, infrastructure software, and distribution services, each purpose-built to advance and scale the Ethena ecosystem. As stablecoins increasingly serve as foundational infrastructure for global payments, decentralized finance, and digital capital markets, StablecoinX combines the accessibility of a public listing with direct participation in one of the fastest-growing segments of global finance.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the U.S. federal securities laws, including expectations, intentions, plans, prospects regarding StablecoinX’s expectations with respect to future performance, its vision and business strategy. These forward-looking statements are generally identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “potential,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events or conditions that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, but not limited to, the failure of StablecoinX to maintain the listing of its shares of Class A common stock; costs incurred as a result of StablecoinX becoming a public company; changes in business, market, financial, political and regulatory conditions; risks relating to StablecoinX’s operations and business; the risk that the anticipated benefits of the business combination may not be realized; the highly volatile nature of the price of ENA and other products issued by Ethena; risks related to increased competition in the industries in which StablecoinX operates; risks relating to significant legal, commercial, regulatory and technical uncertainty regarding crypto assets, including stablecoins; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; risks that StablecoinX experiences difficulties managing its growth and expanding operations; challenges in implementing StablecoinX’s business plan including developing and launching its infrastructure services, StablecoinX Harness middleware and distribution services, whether due to operational challenges, significant competition and regulation or other reasons; the outcome of any potential legal proceedings that may be instituted against StablecoinX or others relating to the business combination, and other risks and uncertainties described in the filings of StablecoinX with the Securities and Exchange Commission (the “SEC”). The inclusion of any statement in this press release does not constitute an admission by StablecoinX or any other person that the events or circumstances described in such statement are material.

The foregoing list of risk factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the final prospectus filed by the Company on September 14, 2026, and the other documents that have been filed by StablecoinX with the SEC and other documents to be filed by StablecoinX from time to time with the SEC. These filings do or will identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. There may be additional risks that StablecoinX does not presently know or that StablecoinX currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. 

Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and StablecoinX assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. StablecoinX does not give any assurance that either it will achieve its expectations. The inclusion of any statement in this press release does not constitute an admission by StablecoinX or any other person that the events or circumstances described in such statement are material.

Contacts

Investor Relations

Adele Carey
SVP, Investor Relations
stablecoinxir@allianceadvisors.com

Media Relations

Aayushi
PR & Media Associate
aayushi@allianceadvisors.com

ROSELAND, N.J., Nov. 11, 2026 (GLOBE NEWSWIRE) — Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Wednesday, November 13, 2026, to discuss the company’s financial results for the third quarter ended September 30, 2026, as well as the company’s corporate progress and other developments.

The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or 973-528-0011 for international callers and by entering the access code: 612206. A live webcast and replay are available here: https://www.webcaster5.com/Webcast/Page/2306/54665.

An audio replay of the call will be available through November 27, 2026, and can be accessed by dialing 877-481-4010 for U.S. callers or 919-882-2331 for international callers and by entering the access code: 54665.

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a technology-focused medical research and development company that patents, designs, and develops innovative injection technologies and instruments for medical and dental applications. Milestone Scientific’s computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety. Their proprietary DPS Dynamic Pressure Sensing Technology® instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. To learn more, view the MLSS brand video or visit milestonescientific.com.

Contact:

HAYDEN IR:

James Carbonara
(646)-755-7412
james@haydenir.com

Brett Maas
(646) 536-7331
brett@haydenir.com

SEOUL, South Korea, Nov. 11, 2026 (GLOBE NEWSWIRE) — DoubleDown Interactive Co., Ltd. (NASDAQ: DDI) (“DoubleDown” or the “Company”), a leading developer and publisher of digital games on mobile and web-based platforms, today announced unaudited financial results for the third quarter ended September 30, 2026.

Third Quarter 2026 vs. Third Quarter 2025 Summary:

  • Revenue decreased 1.6% to $94.3 million in the third quarter of 2026 compared to $95.8 million in the third quarter of 2025.
    • Revenue from the Company’s social casino/free-to-play games was $76.8 million in the third quarter of 2026, a 3.5% decrease from the third quarter of 2025. The decrease was primarily due to lower revenue from the Company’s DoubleDown titles (excluding WHOW Games).
    • Direct-to-Consumer (“DTC”)1 revenue rose to $44.6 million in the third quarter of 2026, compared to $16.6 million in the third quarter of 2025. DTC revenue as a percentage of total social casino revenue increased to 58.0% in the third quarter of 2026 from 20.9% in the third quarter of 2025 and 52.4% in the second quarter of 2026.
    • Revenue from SuprNation, the Company’s iGaming subsidiary, increased 7.4% year-over-year to $17.4 million, primarily as a result of the continued success of the Company’s newest brand, Los Vegas.
  • Operating expenses decreased to $56.8 million in the third quarter of 2026 from $60.9 million in the third quarter of 2025, primarily reflecting lower platform fees as a greater share of social casino revenue was generated through DTC channels, partially offset by higher gaming duties in the iGaming segment.
  • Profit for the interim period (excluding non-controlling interest) decreased 43.9% to $18.4 million, or earnings per fully diluted common share of $7.41 ($0.37 per American Depositary Share (“ADS”)), in the third quarter of 2026, compared to $32.7 million, or earnings per fully diluted common share of $13.21 ($0.66 per ADS), in the third quarter of 2025.
    • The decline primarily reflects net foreign currency losses recognized in the third quarter of 2026, mainly unrealized and realized losses on U.S. dollar-denominated financial assets as well as higher income tax expense. These factors were partially offset by higher operating profit, which increased to $37.5 million from $35.0 million, driven by lower cost of revenue attributable to a higher proportion of DTC revenue.
    • Each ADS represents 0.05 share of a common share.
    • Adjusted EBITDA rose 7.2% to $40.2 million for the third quarter of 2026, compared to $37.5 million in the third quarter of 2025. Adjusted EBITDA margin increased to 42.7% in the third quarter of 2026, compared to 39.1% in the third quarter of 2025.
  • Beginning in the fourth quarter of 2025, social casino KPIs are inclusive of those from WHOW Games.
    • Payer Conversion ratio for the Company’s social casino/free-to-play games increased to 9.5% in the third quarter of 2026 from 7.8% in the third quarter of 2025, primarily as a result of the inclusion of WHOW Games, which has a higher Payer Conversion ratio.
    • Average Revenue Per Daily Active User (“ARPDAU”) for the Company’s social casino/free-to-play games increased to $1.44 in the third quarter of 2026 from $1.39 in the third quarter of 2025, primarily as a result of the inclusion of WHOW Games, which has a higher Payer Conversion ratio that more than offset its lower average revenue per payer.
    • Average monthly revenue per payer for the social casino/free-to-play games decreased to $216 in the third quarter of 2026 from $272 in the third quarter of 2025, primarily as a result of the inclusion of WHOW Games, which has a lower average revenue per payer.
  • Net cash flows from operating activities decreased to $23.6 million in the third quarter of 2026 from $33.4 million in the third quarter of 2025. The decrease is primarily due to higher income taxes paid.

______________________________
1
Direct-to-Consumer revenue represents revenue from purchases made through Company-owned channels, including web storefront transactions and other direct payment flows.

“Following our strong results in the first half of 2026, DoubleDown’s third quarter results reflect another period of solid performance, and exceeded consensus expectations for revenue and Adjusted EBITDA. Operational excellence drove our operating profit to $37.5 million and a 7.2% year-over-year growth in adjusted EBITDA and expanded our third quarter adjusted EBITDA margin to 42.7%. Direct-to-Consumer expansion continues, with revenue of $44.6 million in the third quarter representing 58% of social casino revenue, up from 52% last quarter and 21% a year ago.

“Our ability to consistently drive a high conversion of revenue to cash flow remains a top operating priority, and enabled DoubleDown to generate $23.6 million of net cash flow from operations in the third quarter and a total of $94.7 million in the first nine months of 2026.

“Looking ahead, we remain focused on execution across our social casino and iGaming portfolio while continuing to evaluate acquisitions in casual gaming, online gambling and mobile entertainment. With an aggregate net cash position of $545 million, DoubleDown’s strong balance sheet provides us with substantial financial flexibility to pursue strategic growth opportunities and value-building initiatives and transactions that build long-term shareholder value.”

Summary Operating Results for DoubleDown Interactive (Unaudited)

  Three months ended September 30,   Nine months ended September 30,
    2026     2025       2026     2025  
Revenue ($ MM) $ 94.3   $ 95.8     $ 282.7   $ 264.2  
Total operating expenses ($ MM)   (56.8 )   (60.9 )     (173.3 )   (167.1 )
Profit for the interim period (excluding non-controlling interest) ($ MM) $ 18.4   $ 32.7     $ 86.6   $ 78.4  
Adjusted EBITDA ($ MM) $ 40.2   $ 37.5     $ 117.7   $ 101.8  
Profit margin   19.5 %   34.2 %     30.6 %   29.7 %
Adjusted EBITDA margin   42.7 %   39.1 %     41.6 %   38.5 %
           
Non-financial performance metrics(1)          
Average MAUs (000s)   1,232     1,118       1,284     1,173  
Average DAUs (000s)   575     555       601     580  
ARPDAU $ 1.44   $ 1.39     $ 1.40   $ 1.34  
Average monthly revenue per payer $ 216   $ 272     $ 213   $ 278  
Payer conversion   9.5 %   7.8 %     9.3 %   7.2 %

(1) Social casino/free-to-play games only. The KPIs for the three and nine months ended September 30, 2025 in the table above exclude WHOW Games, which was acquired on July 14, 2025.

Update on Binding Agreement with, and Tender Offer Commenced by, Controlling Shareholder

As previously announced on November 9, 2026, the Company entered into a Tender Offer and Post-Offer Cooperation Agreement with DoubleU Games Co., Ltd. (“DUG”), the Company’s controlling shareholder (the “Agreement”), pursuant to which DUG has commenced a tender offer to acquire all of the outstanding ADSs of the Company not owned by DUG and its affiliates at a price of US$16.25 per ADS in cash, without interest and less any applicable withholding taxes (the “Offer”). The Company’s Board of Directors, following the recommendation of a special committee of independent and disinterested directors, has unanimously approved the Agreement and the transactions contemplated thereby and determined to recommend that holders of ADSs accept the Offer and tender their ADSs. The Offer is subject to various conditions, including a minimum tender condition and a majority-of-the-minority condition, as described in the Offer documents. There can be no assurance that the Offer or the transactions contemplated by the Agreement will be completed. For further information, please refer to the Company’s report on Form 6-K filed with the SEC on November 9, 2026 and the Solicitation/Recommendation Statement on Schedule 14D-9 filed with the SEC on November 10, 2026. Meanwhile, the Company continues to conduct its business and operations in the ordinary course, subject to certain constraints imposed by the Agreement.

Conference Call

DoubleDown will hold a conference call today (November 11, 2026) at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss these results. A question-and-answer session will follow management’s presentation.

To access the call, please use the following link: DoubleDown Third Quarter 2026 Earnings Call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, please register a minimum of 15 minutes before the start of the call.

A simultaneous webcast of the conference call will be available with the following link: DoubleDown Third Quarter 2026 Earnings Webcast, or via the Investor Relations page of the DoubleDown website at ir.doubledowninteractive.com. For those not planning to ask a question on the conference call, the Company recommends listening via the webcast. A replay will be available on the Company’s Investor Relations website shortly after the event.

About DoubleDown Interactive

DoubleDown Interactive Co., Ltd. is a leading developer and publisher of digital games on mobile and web-based platforms. We are the creators of multi-format interactive entertainment experiences for casual players, bringing authentic Vegas entertainment to players around the world through an online social casino experience. The Company’s flagship social casino title, DoubleDown Casino, has been a fan-favorite game on leading social and mobile platforms for years, entertaining millions of players worldwide with a lineup of classic and modern games. DoubleDown’s social casino platform was expanded with WHOW Games GmbH, a developer headquartered in Hamburg, Germany, acquired in 2025. The Company’s subsidiary, SuprNation, operates four real-money iGaming sites in Western Europe.

About DoubleU Games

DoubleU Games Co., Ltd. (KRX: 192080), headquartered in Seoul, is the controlling shareholder of DoubleDown Interactive Co., Ltd., owning approximately 67.05% of its outstanding common shares.

Additional Information and Where to Find It

This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any securities of DoubleDown. This communication is not a substitute for the tender offer materials that DoubleU Games and DoubleDown have filed with the U.S. Securities and Exchange Commission (the “SEC”). DoubleU Games has filed a Tender Offer Statement on Schedule TO (including an Offer to Purchase, a related Letter of Transmittal and other offer documents), DoubleU Games and DoubleDown have jointly filed a Rule 13e-3 Transaction Statement on Schedule 13E-3 (which may be combined with the Schedule TO), and DoubleDown has filed a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the tender offer.

HOLDERS OF ADSs ARE URGED TO READ THE TENDER OFFER MATERIALS (INCLUDING THE OFFER TO PURCHASE, THE RELATED LETTER OF TRANSMITTAL AND OTHER OFFER DOCUMENTS), THE SCHEDULE 13E-3 AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9, AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, CAREFULLY BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT HOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING A TENDER OF THEIR ADSs. These materials are available free of charge on the SEC’s website at www.sec.gov. Free copies of the documents filed by DoubleDown may also be obtained by contacting DoubleDown at ir@doubledown.com or by visiting DoubleDown’s website at https://doubledowninteractive.com.

Contacts:

DoubleU Games Investor Relations — Tel +82-2-501-7216 — Email ir@doubleugames.com

DoubleDown Investor Relations —
               Joe Sigrist, Chief Financial Officer — Tel +1 (206) 773-2266 — Email ir@doubledown.com
               Joseph Jaffoni, Christin Armacost, JCIR — Tel +1 (212) 835-8500 — Email DDI@jcir.com

Georgeson LLC, Information Agent —
               Toll Free +1 (888) 745-7950 (or +1 (516) 454-5409 from outside the U.S. and Canada)
               Email: doubledownoffer@georgeson.com

Safe Harbor Statement

Certain statements contained in this press release are “forward-looking statements” about future events and expectations. Forward-looking statements are based on our beliefs, assumptions, and expectations of industry trends, our future financial and operating performance, and our growth plans, taking into account the information currently available to us. These statements are not statements of historical fact. We have based these forward-looking statements on our current expectations and assumptions about future events. While our management considers these expectations and assumptions to be reasonable, they are inherently subject to significant business, economic, competitive, regulatory and other risks, contingencies and uncertainties, most of which are difficult to predict and many of which are beyond our control. Therefore, you should not place undue reliance on such statements. Words such as “anticipates,” “believes,” “continues,” “estimates,” “expects,” “goal,” “objectives,” “intends,” “may,” “opportunity,” “plans,” “potential,” “near-term,” “long-term,” “projections,” “assumptions,” “projects,” “guidance,” “forecasts,” “outlook,” “target,” “trends,” “should,” “could,” “would,” “will,” and similar expressions are intended to identify such forward-looking statements. We qualify any forward-looking statements entirely by these cautionary factors. We assume no obligation to update or revise any forward-looking statements for any reason or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Use and Reconciliation of Non-IFRS Financial Measures

In addition to our results determined in accordance with IFRS, we believe the following non-IFRS financial measure is useful in evaluating our operating performance. We present “adjusted earnings before interest, taxes, depreciation and amortization” (“Adjusted EBITDA”) because we believe it assists investors and analysts by facilitating comparison of period-to-period operational performance on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. The items excluded from the Adjusted EBITDA may have a material impact on our financial results. Certain of those items are non-recurring, while others are non-cash in nature. Accordingly, the Adjusted EBITDA is presented as supplemental disclosure and should not be considered in isolation from, as a substitute for, or superior to, the financial information prepared in accordance with IFRS, and should be read in conjunction with the condensed consolidated interim financial statements furnished in our report on Form 6-K filed with the SEC.

In our reconciliation from our reported IFRS “profit before income tax” to our Adjusted EBITDA, we eliminate the impact of the following four line items: (i) depreciation and amortization; (ii) finance income; (iii) finance cost; and (iv) other (income) expense. The below table sets forth the full reconciliation of our non-IFRS measures:

Reconciliation of non-IFRS measures Three months ended September 30,   Nine months ended September 30,
(in millions, except percentages)   2026     2025       2026     2025  
Profit for the interim period $  18.4    $  32.8      $  86.6    $  78.5   
Income tax expense    10.9       8.4         29.5       26.0   
Profit before income tax    29.3       41.1         116.1       104.5   
           
Adjustments for:          
Depreciation and amortization    2.7       2.5         8.2       4.8   
Finance income    (1.8  )    (4.5  )      (18.0  )    (12.9  )
Finance cost    10.0       (1.6  )      11.3       5.4   
Other (income) expense, net    —       —         0.1       (0.1  )
Adjusted EBITDA $  40.2    $  37.5      $  117.7    $  101.8   
Adjusted EBITDA margin    42.7  %    39.1  %      41.6  %    38.5  %

We encourage investors and others to review our financial information in its entirety and not to rely on any single financial measure.

DoubleDown Interactive Co., Ltd.
Consolidated Interim Statement of Financial Position
(In thousands of U.S. dollars)
 
  September 30,   December 31,
    2026       2025  
  (unaudited)    
Assets      
Cash and cash equivalents $ 483,448     $ 388,891  
Short-term investments   98,633       101,142  
Accounts receivable, net   40,274       32,017  
Prepaid expenses and other assets   5,686       5,523  
Total current assets $ 628,041     $ 527,573  
Property and equipment, net   932       1,084  
Right-of-use assets, net   4,565       4,273  
Intangible assets, net   72,090       79,866  
Goodwill   425,030       426,659  
Deferred tax asset   —       180  
Other non-current assets   968       906  
Total non-current assets $ 503,585     $ 512,968  
Total assets $ 1,131,626     $ 1,040,541  
Liabilities and equity      
Accounts payable and accrued expenses $ 22,629     $ 24,564  
Current lease liabilities   2,168       1,444  
Income taxes payable   216       3,674  
Contract liabilities   1,497       1,861  
Current portion of borrowings with related party   —       34,846  
Other current liabilities   1,237       1,760  
Total current liabilities $ 27,747     $ 68,149  
Long-term borrowings with related party   36,808       —  
Non-current lease liabilities   2,953       3,309  
Deferred tax liabilities   25,041       17,360  
Other non-current liabilities   1,533       1,338  
Total non-current liabilities $ 66,335     $ 22,007  
Total liabilities $ 94,082     $ 90,156  
Equity      
Share capital   21,198       21,198  
Share premium   359,280       359,280  
Accumulated comprehensive loss   (4,379 )     (4,904 )
Retained earnings   661,232       574,623  
Equity attributable to DoubleDown Interactive Co., Ltd. $ 1,037,331     $ 950,197  
Equity attributable to non-controlling interests   213       188  
Total equity $ 1,037,544     $ 950,385  
Total liabilities and equity $ 1,131,626     $ 1,040,541  
               

DoubleDown Interactive Co., Ltd.
Consolidated Interim Statement of Comprehensive Income
(Unaudited, in thousands of U.S. dollars, except per share amounts)
 
  Three months ended September 30,   Nine months ended September 30,
    2026       2025       2026       2025  
Revenue $ 94,271     $ 95,847     $ 282,681     $ 264,152  
Operating expenses:              
Cost of revenue   (22,170 )     (27,888 )     (69,646 )     (75,700 )
Sales and marketing   (15,063 )     (15,736 )     (46,327 )     (42,961 )
Research and development   (3,051 )     (4,192 )     (10,591 )     (9,879 )
General and administrative   (16,481 )     (13,025 )     (46,594 )     (38,652 )
Other income   (3 )     28       76       213  
Other expense   (6 )     (47 )     (192 )     (141 )
Total operating expenses $ (56,774 )   $ (60,860 )   $ (173,274 )   $ (167,120 )
Operating profit $ 37,497     $ 34,987     $ 109,407     $ 97,032  
Finance income   1,771       4,526       18,021       12,872  
Finance cost   (9,976 )     1,610       (11,325 )     (5,383 )
Profit before income tax $ 29,292     $ 41,123     $ 116,103     $ 104,521  
Income tax expense   (10,931 )     (8,362 )     (29,469 )     (25,974 )
Profit for the interim period $ 18,361     $ 32,761     $ 86,634     $ 78,547  
Other comprehensive income (loss):              
Items that will not be reclassified subsequently to profit or loss:              
Pension adjustments, net of tax   4       39       266       139  
Items that may be reclassified subsequently to profit or loss:              
Gain (loss) on foreign currency translation, net of tax   7,765       (1,920 )     259       5,207  
Total comprehensive income for the interim period $ 26,130     $ 30,880     $ 87,159     $ 83,893  
Profit attributable to:              
DoubleDown Interactive Co., Ltd.   18,355       32,721       86,609       78,409  
Non-controlling interests   6       40       25       138  
Total comprehensive income attributable to:              
DoubleDown Interactive Co., Ltd.   26,124       30,840       87,134       83,755  
Non-controlling interests   6       40       25       138  
               
Earnings per share:              
Basic $ 7.41     $ 13.21     $ 34.96     $ 31.65  
Diluted $ 7.41     $ 13.21     $ 34.96     $ 31.65  
Weighted average shares outstanding:              
Basic   2,477,672       2,477,672       2,477,672       2,477,672  
Diluted   2,477,672       2,477,672       2,477,672       2,477,672  
                               

DoubleDown Interactive Co., Ltd.
Consolidated Interim Statement of Cash Flows
(Unaudited, in thousands of U.S. dollars)
 
  Nine months ended September 30,
    2026       2025  
Cash flows from operating activities      
Profit for the interim period $ 86,634     $ 78,547  
Adjustments to reconcile profit to net cash from operating activities:      
Depreciation and amortization   8,166       4,801  
Unrealized gain on foreign currency   (582 )     (366 )
Unrealized loss on foreign currency   3,995       445  
Gain on foreign currency transaction   (3,146 )     (279 )
Loss on foreign currency transaction   5,352       1,527  
Gain on disposal of financial assets and liabilities   (661 )     (18 )
Loss on valuation of financial assets and liabilities   61       881  
Interest income   (13,419 )     (12,126 )
Interest expense   1,434       1,423  
Miscellaneous income   (3 )     —  
Miscellaneous expense   92       —  
Provision for severance benefits   277       349  
Other long-term employee benefits   116       913  
Income tax expense   29,469       25,974  
Working capital adjustments:      
Accounts receivable, net   (8,372 )     1,103  
Prepaid expenses, and other assets   336       559  
Other non-current assets   101       92  
Accounts payable and accrued expenses   104       2,893  
Contract liabilities   (364 )     (442 )
Other current and non-current liabilities   (654 )     (3,212 )
Cash generated from operations $ 108,936     $ 103,064  
Interest received   14,069       13,779  
Interest paid   (3,377 )     (198 )
Income taxes paid   (24,977 )     (22,508 )
Net cash inflow from operating activities $ 94,651     $ 94,137  
Cash flows from investing activities      
Purchase of property and equipment   (186 )     (174 )
Disposal of property and equipment   5       4  
Purchase of intangible assets   (5 )     —  
Disposal of financial assets at fair value through profit or loss   705       —  
Acquisition of WHOW Games   —       (61,570 )
Purchase of financial assets at fair value through profit or loss   —       (9,815 )
Purchase of short-term investments   (265,742 )     (186,148 )
Disposal of short-term investment   267,732       178,009  
Net cash inflow (outflow) from investing activities $ 2,509     $ (79,694 )
Cash flows from financing activities      
Repayment of lease liabilities   (1,449 )     (848 )
Net cash outflow from financing activities $ (1,449 )   $ (848 )
Net increase in cash and cash equivalents $ 95,711     $ 13,595  
Effect of exchange rate changes on cash and cash equivalents $ (1,154 )   $ (107 )
Cash and cash equivalents at beginning of the interim period $ 388,891     $ 334,850  
Cash and cash equivalents at end of the interim period $ 483,448     $ 348,338  

Rehovot, Israel, Nov. 11, 2026 (GLOBE NEWSWIRE) — Maris-Tech Ltd. (Nasdaq: MTEK, MTEKW) (“Maris-Tech” or the “Company”), a global leader in edge computing, artificial intelligence (“AI”), and video intelligence solutions for defense applications, today announced that it has received a written notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a grace period of 180 calendar days to regain compliance with the minimum bid price requirement. The Notice has no immediate effect on the Company’s Nasdaq listing or the trading of its ordinary shares and publicly traded warrants, and during the grace period, as may be extended, the Company’s ordinary shares and publicly traded warrants will continue to trade on the Nasdaq Capital Market under the symbol “MTEK” and “MTEKW”, respectively.

According to the Notice, the Company has until May 10, 2027, to regain compliance with the minimum bid price requirement. The Company can regain compliance if, at any time during this 180-day period, the closing bid price of its ordinary shares is at least $1.00 for a minimum of ten consecutive business days, in which case the Company will be provided with written confirmation of compliance and this matter will be closed. However, Nasdaq may, in its discretion, require the Company’s ordinary shares to maintain a bid price of at least $1.00 for a period in excess of ten consecutive business days, but generally no more than 20 consecutive business days, before determining that the Company has demonstrated an ability to maintain long-term compliance. In the event that the Company does not regain compliance after the initial 180-day period, the Company may then be eligible for an additional 180-day compliance period if it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the minimum bid price requirement. In this case, the Company will need to provide written notice of its intention to cure the deficiency during the second compliance period.

If the Company cannot demonstrate compliance by the allotted compliance period(s), Nasdaq’s staff will notify the Company that its ordinary shares and warrants are subject to delisting.

Maris-Tech’s continued listing on Nasdaq remains a key priority for the Company. Should the situation not resolve itself over the above-mentioned timeframes, the Company intends to consider available options to cure the deficiency and regain compliance with the minimum bid price requirement within the compliance period, including a potential reverse share split.

About Maris-Tech Ltd.

Maris-Tech delivers AI-powered edge video solutions for mission-critical defense and security operations, enabling real-time situational awareness, intelligence gathering, and surveillance in bandwidth- and latency-constrained environments. Trusted by leading security organizations, Maris-Tech platforms are deployed across UAVs, UGVs, armored vehicles, and dismounted soldier systems, supporting missions that require ultra-low-latency video processing and onboard AI analytics. From intelligence collection in extreme conditions to AI-driven surveillance and terrain dominance, Maris-Tech masters the AI video pipeline at the edge through best-in-class SWaP-optimized, ruggedized computing solutions.

For more information, visit https://www.maris-tech.com/

Forward-Looking Statements Disclaimer

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe”, “expect”, “may”, “should”, “could,” “seek”, “intend”, “plan”, “goal”, “estimate”, “anticipate” or other comparable terms. For example, we are using forward-looking statements when we are discussing regaining compliance with Nasdaq’s continued listing requirements, and the timing and effect thereof. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to successfully market our products and services, including in the United States; the acceptance of our products and services by customers; our continued ability to pay operating costs and ability to meet demand for our products and services; the amount and nature of competition from other security and telecom products and services; the effects of changes in the cybersecurity and telecom markets; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, strategic alliance agreements, licensing and supplier arrangements; our ability to comply with applicable regulations; and the other risks and uncertainties described in the Annual Report on Form 20-F for the year ended December 31, 2025, filed with the U.S, Securities and Exchange Commission (the “SEC”) on May 15, 2026, and our other filings with the SEC. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Relations:

Nir Bussy, CFO
Tel: +972-72-2424022
Nir@maris-tech.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.